All News
FDA Approves IV Secukinumab
On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
Read Article
Surprising Link Between Weight Gain and RA Activity
d
MedPage Today
In patients with rheumatoid arthritis (RA) treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.
Read Article
Shoulder Arthralgias
Featuring Dr. David Liew (Melbourne, Australia) ( @drdavidliew )
Cancer, checkpoint inhibitors and arthralgias. #PMR
https://t.co/FRpIzfnW76 https://t.co/2S3PP1WA3O
Dr. John Cush RheumNow ( View Tweet)
342 systemic sclerosis pts, ~32% report reproductive probs:
-early menopause onset (45 vs 48y)
-menopause effected by SSc onset & digital ulcers
-More spont Abs(12 vs 4%), premies (22 vs 6%), low birth Wt (27 vs 5%), C-section (49 vs 19%); NOT Infertility https://t.co/Tjjl9sxtja https://t.co/LKzyGR0mlE
Dr. John Cush RheumNow ( View Tweet)
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/P4Vv2L3u24 https://t.co/ZYBPcgXNi8
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety and Efficacy in bDMARD-IR Patients with RA
View 5-year long-term extension outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. This poster is sponsored by AbbVie US Medical Affairs.https://t.co/Qr3KJXZJOe https://t.co/Ri1eS0q9Rb
Dr. John Cush RheumNow ( View Tweet)
Difficult #PMR Management
Featuring Dr. Sebastian Sattui (Pittsburgh, PA) PMR with Difficulty Weaning plus Synovitis. QD Clinics are video vignettes with lessons from the clinic.
https://t.co/dLYxwrmbJg
@sattuiSEMD https://t.co/FDuHWJT7Ra
Dr. John Cush RheumNow ( View Tweet)
PMR & Popeye's Spinach
Dr. Jack Cush reviews the big #PMR reports from this week along with other journal reports from RheumNow.
https://t.co/7oCQmuSATE https://t.co/5qWfZZzNBn
Dr. John Cush RheumNow ( View Tweet)
Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis #RA
https://t.co/BhAKRXuzMY https://t.co/MqVHMieqiz https://t.co/zCvO2FbrZA
Dr. John Cush RheumNow ( View Tweet)
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9
Dr. John Cush RheumNow ( View Tweet)
Tuesday 10/10--this webinar focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew.
https://t.co/4PefLrRoBx
@drmaxyates1 @richardpaconway @drdavidliew https://t.co/089UBUsJLj
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatologist SURVEY Question: How often do you start a new PMR patient on 20mg or more of prednisone? Answer here>> https://t.co/beYWFwK1LX
Links:
Dr. John Cush RheumNow ( View Tweet)
Sustained Efficacy of Bimekizumab in PsA
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr
Dr. John Cush RheumNow ( View Tweet)
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/dC9Z7UgkcO https://t.co/44QEittlEX
Dr. John Cush RheumNow ( View Tweet)
2005 study of 364 PMR pts (age 73.4 yrs) - 284 Rx w/ steroids, predictors of relapse =higher initial CS dose & faster CS tapering. Relapse 4-fold higher when the CS tapering rate was fast (HR 4.27). Minimize initial CS dose and taper CS slowly!! https://t.co/hUpBO7fEgh https://t.co/fv9txM0BeH
Dr. John Cush RheumNow ( View Tweet)
Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of idiopathic inflammatory myopathies:
- incidence 0.2 - 2 per 100,000 PYs
- prevalence 2 - 25 per 100,000
#s vary w/ age/gender & geography; BUT is still unreported in South America, Africa & Asia https://t.co/fRUNV75xQL
Dr. John Cush RheumNow ( View Tweet)
New download on #PMR available now!
https://t.co/esSuRBwSr0 https://t.co/7d2B2x63tF
Dr. John Cush RheumNow ( View Tweet)
Steroid Tapering in #PMR: What's the Gold Standard?
Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica.
https://t.co/oXVrHuHE58 https://t.co/fHNXodtAeV
Dr. John Cush RheumNow ( View Tweet)